Ocular Therapeutix
OCUL
37 hedge funds and large institutions have $179M invested in Ocular Therapeutix in 2014 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 16 increasing their positions, 8 reducing their positions, and 6 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 8
67% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 6
65% more capital invested
Capital invested by funds: $108M → $179M (+$70.6M)
9% more funds holding
Funds holding: 34 → 37 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$4.68M |
| 2 |
Principal Financial Group
Des Moines,
Iowa
|
+$2.09M |
| 3 |
RIM
RS Investment Management
San Francisco,
California
|
+$1.93M |
| 4 |
LCP
Lamond Capital Partners
San Francisco,
California
|
+$1.25M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$793K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$3.33M |
| 2 |
PCM
Pentwater Capital Management
Naples,
Florida
|
-$1.51M |
| 3 |
Morgan Stanley
New York
|
-$855K |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$587K |
| 5 |
Millennium Management
New York
|
-$323K |
OCUL Hedge Fund Activity: Q4 2014 in Review
37 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q4 2014, worth a combined $179M — up 65% from $108M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new OCUL positions and 6 closed out — a net gain of 4 holders — while 16 added to existing stakes and 8 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $4.68M. The largest seller was Sabby Management, cutting an estimated $3.33M.
- 37 institutional investors held Ocular Therapeutix (OCUL) as of Q4 2014, up from 34 in Q3 2014.
- Funds reported $179M of Ocular Therapeutix stock for Q4 2014, up 65% quarter-over-quarter.
- 10 funds opened new Ocular Therapeutix positions in Q4 2014 and 6 closed out, a net change of +4 holders.
- The largest Ocular Therapeutix buyer in Q4 2014 was Fidelity Investments, an estimated $4.68M added.
- The largest Ocular Therapeutix seller in Q4 2014 was Sabby Management, an estimated $3.33M sold.
Based on aggregated 13F filings for Q4 2014.